Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

Abstract

An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochemicals, benzalkonium chloride, a sterile water solution, and folic acid.

Description

CROSS REFERENCES TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 084,759 filed on Feb. 26, 2002 which in turn is a continuation of U.S. Ser. No. 08 / 824,041 filed on Mar. 26, 1997, now U.S. Pat. No. 6,350,784, which in turn is a continuation-in-part of U.S. Ser. No. 08 / 646,988 filed on May 8, 1996, now U.S. Pat. No. 6,355,684, which in turn is a continuation-in-part of U.S. Ser. No. 08 / 600,217, filed on Feb. 12, 1996, now U.S. Pat. No. 6,348,503.BACKGROUND OF THE INVENTION [0002] The present invention relates to human immunedeficiency virus, and more particularly, to medical treatments and preventions for human immunedeficiency virus and other microbial infections. [0003] It has been reported that there are currently about 22 million people infected with human immunedeficiency virus (HIV) throughout the world. The largest proportion of new HIV cases have originated in Africa and the Caribbean. The typical progression of HIV inf...

AI Technical Summary

Benefits of technology

The present invention provides an improved medical treatment and medicine that can inhibit the attachment of human immunedeficiency virus (HIV) to target cells and prevent its spread. The treatment is safe, effective, and can be used for both prevention and treatment of infections caused by HIV and other microbes. The medicine can be applied systemically or topically, and can be made from readily available, over-the-counter chemicals or products. The invention also includes a novel method and process for treating infectious diseases caused by microbes. The microbial inhibitors can be applied and maintained on the microbial infected areas until the external symptoms and physical manifestations of the infection disappear, reside or resolve. The improved medicine can decrease the viral load of patients infected with HIV, and can be used for both prevention and treatment of infections caused by HIV and other microbes.

Problems solved by technology

RT inhibitors can interrupt this process.

Without the protease enzyme, viral structural proteins cannot be manufactured properly, and faulty, non-infectious virus is formed.

Sometimes, the cocktails have been toxic and ineffective for some patients.

Clinical benefit in terms of improved survival or reduced disease progression rate, however, has not yet been fully demonstrated for combination (cocktails) of RT inhibitors and protease inhibitors.

A three-drug combination of AZT plus 3TC plus ritonavir protease inhibitors can cost a patient over U.S. $1,000 / month.

Although, protease inhibitors may be helpful, the medical community and society have not yet resolved patient cost problems for these expensive drugs.

Some individuals who have the trigeminal nerve compromised with oral herpes, have excruciating facial pain, difficulty swallowing, eating and facial swelling.

Individuals with the sacral nerve affected have severe upper leg pain, swelling, and great difficulty walking.

HSV 1 and HSV 2 infections pose very serious health threats often causing: blindness; increased cancer risk of the cervix; aseptic meningitis and encephalitis; neonatal deaths; viremia; etc.

HSV is responsible for serious psychological and emotional distress as well as substantial economic loss to the nation and the world.

Most prior treatments have proven disappointing.

However, acyclovir is only successful in interrupting the replication of the virus.

It is not successful in treating an infectious outbreak either systemically or topically.

Individuals with Auto Immune Deficiency Syndrome (AIDS) are seriously immune-compromised and suffer especially debilitating outbreaks of HSV.

Additionally, AIDS individuals may carry acyclovir resistant strains of HSV, which can make acyclovir ineffective for these individuals.

Images